AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01698307 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional Step-care Algorithm
Description: Step-care algorithm that specifies treatment escalation solely on the basis of symptoms quantified using the Harvey Bradshaw Score.
Study NCT01648556 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood tests and bone marrow biopsy repeated
Description: Blood tests are realized for the dosage of the TPO, the dosage of the antiplatelet antibodies, to measure isotopic lifetime of platelet.~The test in corticoids by the prednisone per os is realized too. The bone marrow biopsy is realized at the inclusion and during follow-ups if the haemogram is abnormal.
Study NCT00686556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Beginning on day -3, use intravenous route between days -3 and +5, followed by oral administration on Day +6 through +30, if tolerated. 15mg/kg/dose for patients \<40 kg, 3 gm/day for patients >40 kg.
Study NCT00686556 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total marrow irradiation
Description: Dose escalating schedule per Cohort (TMI: 300 cGy) once daily.
Study NCT00686556 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: umbilical cord blood transplantation
Description: product will be infused via intravenous drip on Day 0 according to current University of Minnesota guidelines for Umbilical Cord Blood Grafts
Study NCT00686556 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor
Description: 5 mcg/kg/day intravenous or subcutaneous based on body weight beginning on Day +1 after umbilical cord blood infusion until absolute neutrophil count exceeds 2.5 x 10\^9/L for 3 consecutive days.
Study NCT03870594 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: glycated hemoglobin
Description: hemoglobin A1c level in blood
Study NCT04349592 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablet
Description: Oral, one tablet three times a day for 7 days
Study NCT04349592 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: Oral 2 capsules on day one, followed by 1 capsule once a day for days 2-5.
Study NCT04349592 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo capsules
Description: Oral 2 capsules on day one, followed by 1 capsule once a day for days 2-5.
Study NCT01798732 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Selective Laser Trabeculoplasty (Tango Laser, Ellex)
Description: One session of selective laser trabeculoplasty with the following parameters (inferior half-circumference, 50 shots, 0.8 to 1.3 mJ)
Study NCT00669942 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIN457
Description: AIN457A is a fully human recombinant IgG1 antibody that targets and neutralizes IL-17A.
Study NCT03457779 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose
Description: The first 4 patients enrolled on trial will undergo the research core biopsies of their TNBC without the 13C glucose infusion; these samples will serve as control tissue that will be processed identically to the tissues obtained from patients who received the glucose isotope.~The following 12 patients will receive 6 grams (g) of \[1,2-13C\] glucose as an IV
Study NCT03940183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trelagliptin Succinate
Description: the experimental group will use trelagliptin succinate 100 mg for 24weeks
Study NCT03940183 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: the placebo Comparator groups use placebo oral tablet for 24weeks
Study NCT02507037 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: gum+PEG
Description: chew sugarless gum
Study NCT02507037 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: polyethylene glycol
Description: 2L PEG
Study NCT01004198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP4OX
Description: 4.3 g/dL PEG-Hb solution in lactated electrolyte solution
Study NCT01004198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringers Lactate solution
Description: Ringers Lactate solution for Injection
Study NCT00680238 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Human derived FSH
Description: Customized for each patient
Study NCT00680238 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human derived FSH
Description: Customized for each patient
Study NCT04389437 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ophthalmological exam
Description: OCT-A and AO
Study NCT04389437 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ophthalmological exam
Description: OCT-A and AO
Study NCT04389437 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood pressure measurement
Description: Blood pressure measurement before the ophthalmological exam
Study NCT04389437 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood pressure measurement
Description: Blood pressure measurement before the ophthalmological exam
Study NCT02571907 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zenith® Branch Endovascular Graft-Iliac Bifurcation,
Description: Implantation of the Zenith® Branch Endovascular Graft-Iliac Bifurcation.
Study NCT02571907 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Atrium iCAST™
Description: Implantation of Atrium iCAST
Study NCT02571907 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zenith® Flex AAA Endovascular Graft
Description: Implantation of the Zenith Flex Endovascular Graft
Study NCT00532675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589
Description: PAN 5 mg and PAN 20 mg capsules
Study NCT00532675 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide 5mg or 25 mg
Study NCT01337999 — intervention group
Intervention type: OTHER
Intervention: blood draws
Description: 5 blood draws during ovulatory menstrual cycles in premenopausal women
Study NCT04552145 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: standard decompression surgery
Study NCT04552145 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: 3 month physical therapy treatment including home activity based on a well defined program and 4 to 6 visits at physical therapy intervention center.
Study NCT03844711 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical diaphragmatic stimulation (TEDS)
Description: * Stage I: In the first day (group 1) the parameters will be with 30 Hz frequency and the second day (group 2) will be with 80 Hz, with one-day interval between interventions. The TEDS will be applied with symmetrical biphasic pulsed current, pulse width 0.4 ms, rise time of 1 second (s), 1s lift, 2 s descent, maintaining respiratory rate of 15 rpm, intensity required to obtain visible muscle contraction, for 20 minutes or until muscle fatigue.~* Stage II and III:The TEDS will be applied with symmetrical biphasic pulsed current, the parameters will be with 30 Hz frequency, pulse width 0.4 ms, rise time of 1 second (s), 1s lift, 2 s descent, maintaining respiratory rate of 15 rpm, intensity required to obtain visible muscle contraction, for 20 minutes or until muscle fatigue.
Study NCT03844711 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Description: - Stage II and III: The training will start with a minimum load of 50% and will be progressed until reaching 60% of the PImax. Inspiratory muscle training will start with a minimum load of 50% and progress to 60% of the MIP. The patients will perform daily training, being two sets of 30 breaths, one in the morning and one in the afternoon.
Study NCT03844711 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Description: - Stage III: It consists of ventilatory exercises, bronchial hygiene techniques, passive, active-assisted or active exercises for upper and lower limbs, and resistance exercises.
Study NCT03844711 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy
Description: - Stage III: It consists of ventilatory exercises, bronchial hygiene techniques, passive, active-assisted or active exercises for upper and lower limbs, and resistance exercises.
Study NCT00000460 — intervention group
Intervention type: BEHAVIORAL
Intervention: Low intensity exercise
Study NCT00000460 — intervention group
Intervention type: BEHAVIORAL
Intervention: High intensity exercise
Study NCT03816540 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HRV and respiratory coherence biofeedback
Description: Biofeedback treatment to support self-regulatory processes on the physiological level: heart rate variability (HRV) and respiratory coherence.
Study NCT03816540 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HRV and respiratory coherence biofeedback
Description: Biofeedback treatment to support self-regulatory processes on the physiological level: heart rate variability (HRV) and respiratory coherence.
Study NCT02508558 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: motion perception and locomotor operation performance measurements
Study NCT02508558 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: parabolic flight
Study NCT04015375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapsone gel 7.5% (Torrent Pharmaceuticals Ltd)
Description: Topical gel
Study NCT04015375 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACZONE® (dapsone) gel, 7.5% (Allergan, INC.)
Description: Topical gel
Study NCT04015375 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Dapsone gel 7.5% (Torrent Pharmaceuticals Ltd)
Description: Topical gel
Study NCT04605705 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Optimization of the cardiac output, the temperature, the hemoglobin in order to have the NIRS value by up to 80%.
Description: Several maneuvers will be performed in case the NIRS values are below 50%, such as an increase in cardiac output, temperature, hemoglobin to optimize the NIRS value by up to 80%.
Study NCT02739633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genexol-PM
Description: 125 mg/m2 given intravenously over 60 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest. Patients will continue until they experience disease progression or significant toxicity.
Study NCT02739633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2 given intravenously for 3 weeks (days 1, 8 and 15) with 1 week rest. Patients will continue until they experience disease progression or significant toxicity.
Study NCT00669942 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to AIN457
Study NCT00686556 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HLA-matched related donor bone marrow
Description: Related donor bone marrow or mobilized stem cells will be collected (target cell dose 5x10\^8 nucleated cells/kg recipient weight, minimum 3x10\^8 nucleated cells/kg recipient weight) and infused without processing on day 0 according to University of Minnesota Blood and Marrow Transplant Program guidelines.
Study NCT02314793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2205
Description: oral
Study NCT02314793 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study NCT01552902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate
Description: Daily oral dosing in the AM ranging from 30- 70 mg. 4 week forced dose titration, 2 week dose maintenance
Study NCT02332707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uprifosbuvir (+) Grazoprevir (+) Ruzasvir
Description: Two FDC tablets, each containing GZR 50 mg + UPR 225 mg + RZR 30 mg (Part B), taken q.d. by mouth.
Study NCT01552902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate Hydrochloride
Description: Daily oral dosing in the AM ranging from 18-72 mg. 4 week force dose titration, 2 week dose maintenance
Study NCT01552902 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily oral dosing in the AM for 6 weeks
Study NCT03892421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m²
Study NCT03892421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC5
Study NCT03892421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine Injection
Description: Cytarabine 2000 mg/m² qd 2 days
Study NCT03892421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 40 mg
Study NCT03892421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim 0.3 MG/ML
Description: One subcutaneous injection daily for 5 days
Study NCT03216382 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Training Technique
Description: The ATT is a 12-minute audio recording that includes sounds and a voice guiding attention to the sounds. The sounds play continuously during the training task.
Study NCT03216382 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Condition
Description: In the control condition, participants listen to an audio recording with the same sounds as the ATT recording, and a voice that delivers placebo instructions.
Study NCT05109455 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MANOSAR®
Description: MANOSAR® is an authorized food supplement that contains D-mannose, Proanthocyanidins, Ursolic Acis, vitamin complexes and ions, and protects against urinary tract infections.
Study NCT05109455 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Proanthocyanidins
Description: The comparator are Proanthocyanidins of continuous-release, which are isolated from cranberry, and prevents the adhesion of uropathogenic bacteria such a E.coli to the wall of the urothelium.
Study NCT03310333 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propess® (dinoprostone)
Description: The inclusion begins after 12 hours of PROM for a pregnant woman who has an unfavourable cervix and no B streptococcus. The case is discussed during the obstetric staff every morning.~If the cervix is unfavourable (cervical Bishop's score \<6), the information of the study is given to the patient and the consent collected.~An antibiotic is started at the beginning of the inclusion by amoxicillin (or clindamycin in case of allergy of amoxicillin) to prevent choroamnionitis.
Study NCT03310333 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cook cervical pipening balloon
Description: • In dinoprostone vaginal group: the device is placed in vaginal fornix by the midwife for maximum 24 hours. If Propess ® is fallen before the first 12 hours, another one could be introduce if the cervix stayed unfavourable.
Study NCT03254576 — intervention group
Intervention type: OTHER
Intervention: Functional MRI
Study NCT03406741 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychometric evaluation
Description: Wechsler type composite scales (WISC)
Study NCT03406741 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: neuropsychological evaluation
Description: Evaluation of child behavior by the Goodman questionnaire: Strengths and Difficulties Questionnaire
Study NCT02789813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: Once oral administration of 500mg before exposure therapy.
Study NCT03167281 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: early tPA and DNase
Description: Early addition of tPA and DNase (immediately at chest tube placement) versus later (24-48 hours) after chest tube placement.
Study NCT03234283 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IRRIS InfraRed - Red Intubation System
Description: IRRIS will be attached to the patient's neck skin just beneath the laryngeal prominence. Tracheal intubation will be performed by using a video-laryngoscope in a standardized Fashion and by guiding the tracheal tube into the Larynx by following the visual Signal on the Screen that is caused by IRRIS. The handling of IRRIS and the Performance of tracheal Intubation will be recorded. Patients will be monitored for safety parameters and possible adverse events during the study until recovered and released from the postoperative care unit.
Study NCT04606680 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heat application at acupoints
Description: 1. The acupoints will be selected as Tianshu, Pishu, shenshu, zhongwan, and zusanli. The location of the acupoints were based on the national GB/T 12346-2006 acupoints standard. The hot sticker will be placed on the patient's acupoints for about 2 hours. This treatment will be applied once every other day, 3 times per week, for 4 consecutive weeks. The treatment will be delayed during the menstrual period.~2. The following lifestyle modification are recommended to help to establish healthy habits:~The proportion of three nutrients in total calories comprises of 55%-65% from carbohydrates, 20%-30% from oils and 15% from protein, and the energy of the whole day distributed to three meals will follow the proportion of 30% for breakfast, 40% for lunch and 30% for dinner. Meanwhile, low-to-moderate intensity physical activities will be instructed to them for at least 5 days per week continually, 30%-50% of the maximum heart rate reserve value will be required.
Study NCT04606680 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medicated plaster at acupoints
Description: 1. The acupoints will be selected as Tianshu, Pishu, shenshu, zhongwan, and zusanli. The location of the acupoints were based on the national GB/T 12346-2006 acupoints standard.The chinese traditional medicine(aconite root, dried ginger, evodia rutaecarpa, clove, cinnamon, etc)in moderation will be grinded into powder，and the powder will be added with a certain amount of flour, and finally they will be blended with ginger juice to the appearance of mud. Next, 10g of the kneaded medicine mud will be taked and applied to the bottom of the ordinary sticker. They will be placed on the patient's acupoints for about 2 hours. The sticker has the same shape as the hot sticker, but it does not have the effect of thermal stimulation and infrared radiation. This treatment will be applied once every other day, 3 times per week, for 4 consecutive weeks. The treatment will be delayed during the menstrual period.~2. Lifestyle modification:It will be performed as the same as the heat application group.
Study NCT04606680 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Herb-partitioned moxibustion at acupoints
Description: 1. The acupoints will be selected as Tianshu, Pishu, shenshu, zhongwan, and zusanli. The location of the acupoints were based on the national GB/T 12346-2006 acupoints standard\[18\]. The chinese traditional medicine(aconite root, dried ginger, evodia rutaecarpa, clove, cinnamon, etc)in moderation will be grinded into powder，and the powder will be added with a certain amount of flour, and finally they will be blended with ginger juice to the appearance of mud. Next, 10g of the kneaded medicine mud will be taked and applied to the bottom of the hot sticker. They will be placed on the patient's acupoints for about 2 hours. This treatment will be applied once every other day, 3 times per week, for 4 consecutive weeks. The treatment will be delayed during the menstrual period.~2. Lifestyle modification:It will be performed as the same as the heat application group.
Study NCT03373903 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study NCT02789813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproic Acid
Description: Once oral administration of 500mg before exposure therapy.
Study NCT03373903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEZ235
Description: oral
Study NCT02789813 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once oral administration of 500mg before exposure therapy.
Study NCT03373903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEZ235 plus everolimus (RAD001)
Description: Oral
Study NCT02642224 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Work Case Management
Description: The National Network of Hospital Violence Intervention (NNHVI) suggests that intervening when gunshot victims are receiving treatment in hospital trauma services may be effective in linking high-risk individuals to appropriate case management services, and that this service linkage may lower the risk of further violence. Our adaptation of the NNHVI model will focus on the social networks of gunshot victims as well as the victims themselves. Intervention efforts will range from job training and mentoring to relocation to different communities.
Study NCT03920644 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Scopolamine Transdermal Patch [Transderm Scop]
Description: Current Motion Sickness treatment, 1 patch behind the ear.
Study NCT03920644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine
Description: IND, up to 6 administration of intranasal gel.
Study NCT03920644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Patch
Description: Placebo Patch, 1 patch behind the ear.
Study NCT03920644 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: Placebo Patch, 1 patch behind the ear.
Study NCT03920644 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gel
Description: Placebo Gel,up to 6 administration of intranasal gel.